How a patient’s T cells are engineered to recognize CD19-positive leukemia cells.

How Tisagenlecleucel works

Tisagenlecleucel is made from a patient’s own T cells, genetically modified to express a chimeric antigen receptor (CAR) directed against CD19. This example follows recognition of a leukemia cell and the subsequent cellular response.

1. Recognize CD19. The receptor’s external recognition component binds CD19. CD19 is present on normal as well as malignant B cells.
2. Transmit the signal. Intracellular CD3 zeta and 4-1BB domains connect recognition to T-cell activation, expansion and persistence.
3. Eliminate the target. Activated CAR T cells can eliminate CD19-expressing cells. The film illustrates one encounter rather than estimating the likelihood of a successful encounter.

The mechanism summary follows section 12.1 of the KYMRIAH prescribing information. Recognition, remission and long-term survival are distinct questions and are presented separately.

For a cell therapy, recognition and the subsequent cellular response are easier to discuss when viewers can inspect each step. This demonstration uses a film for the sequence and a static figure for scientific review and reuse in a presentation.

A six-step cell-therapy mechanism

Six panels show T-cell collection and engineering, infusion, CD19 recognition, CAR signaling, cytotoxic granule release, and expansion and persistence after treatment.

Remission, durability and safety in ELIANA

The evidence brief summarizes early remission after tisagenlecleucel, three-year event-free and overall survival, and selected risks in children and young adults with relapsed or refractory B-cell ALL.

It identifies the enrolled and infused populations and explains why the single-arm results cannot establish superiority over another treatment.

Scientific sources and representation limits

The mechanism summary below the film is based on the primary sources linked here. The source notes describe how those references relate to the visuals.

• KYMRIAH prescribing information: mechanism, clinical studies and safety
• ELIANA original trial publication (Maude et al., 2018)
• CAR-T example: clinical evidence and rendering notes

This leukemia example concerns pediatric and young-adult B-cell ALL. ELIANA is a single-arm study, so remission data should not be treated as a randomized comparison. The example is not a complete safety presentation; the full prescribing information includes serious risks and monitoring requirements.

How this example could support a program

A content foundation for a cell-therapy education program built around the questions of a specific audience. A patient-facing version could introduce the treatment approach in plain language, while a physician version could go deeper into recognition, cellular action and the evidence. Materials would be tailored to the relevant treatment population and safety context.